A Potential Therapy for Rebalancing BMPR2: A New Direction in PAH

Thank you

Thank you for joining us today. Industry Innovations Webinars are archived on the ATS YouTube channel under the Industry Innovation playlist. https://www.youtube.com/playlist?list=PLFyO68a-Ji3n0xo20dmiQGvtDk9e2dKeH

Expect a brief satisfaction survey via email. Your feedback is appreciated as it helps improve programming for the future.

Description

Despite multiple treatment options, patients with PAH still face a devastating and progressive disease. This program will focus on the imbalances in BMPR2 and activin receptor signaling that may drive PAH progression, reviewing the latest data available. A new therapeutic approach that aims to rebalance this signaling will be discussed in the context of potential disease modification.

This program is sponsored by Acceleron.

By registering for this webinar, you agree your information will be shared with the sponsor.

No CME or MOC credits are available for this program.

Opinions expressed and resources shared may not have been reviewed by the ATS prior to distribution through ATS channels, or reflect official positions of the ATS, unless it is explicitly noted as a result of official ATS approval. References to specific commercial entities (companies) or products do not reflect review or endorsement by the ATS unless it is explicitly noted as a result of official ATS approval.

Contributors

Aaron B. Waxman, MD, PhD

Brigham and Women’s Hospital (BWH)
Director, Pulmonary Vascular Disease Program

Dr. Aaron B. Waxman is the director of the Pulmonary Vascular Disease Program at Brigham and Women’s Hospital (BWH). He is also an associate professor of medicine at Harvard Medical School.

After receiving his medical degree from Yale University School of Medicine, Dr. Waxman completed a residency in internal medicine at Yale New Haven Hospital. He then completed two fellowships: the first at Howard Hughes Medical Institute, and the second in pulmonary and critical care at Yale New Haven Hospital. He is board certified in critical care medicine, internal medicine and pulmonary disease.

Dr. Waxman’s clinical interests include pulmonary arterial hypertension (PAH), right heart failure, thromboembolic disease and pulmonary vascular disease. His research focuses on the inflammatory mechanisms of pulmonary vascular remodeling that lead to right heart failure. His research into the regulation of cell death proteins by IL-6 cytokines in mice led to the discovery of a relationship between dyspnea and mitochondrial dysfunction, and resulted in additional clinical studies examining the abnormalities of inflammatory mediators and oxygen extraction in patients with PAH. He has authored over 110 peer-reviewed publications and has received funding from the National Institutes of Health and the National Heart, Lung, and Blood Institute.

Thank you

Description

Contributors

Aaron B. Waxman, MD, PhD